Company Information
Cytos Biotechnology AG
Wagistrasse 25
Postfach
8952 Zürich-Schlieren
Suisse
+41 1 733 47 47
http://www.cytos.com
- CEO
- Wolfgang A. Renner
- Investor Relations
- Jakob Schlapbach
Cytos is a Swiss company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products - the Immunodrugs. Immunodrugs are intended for use in the prevention and treatment of chronic diseases afflicting millions of people worldwide.
Trading Information
- Sector
- Health Care - 4500
- Regulatory Standard
- International Reporting Standard
- Security Number
- 1102521
- ISIN
- CH0011025217
- Symbol
- CYTN
- Index member
- SPI
Intermediaries
- Listing Agent
- Bank Sarasin & Cie
- Lead Bank
- Bank Sarasin & Cie
- Auditor
- PricewaterhouseCoopers AG
Information on the Issue
| Security Details | |
|---|---|
| First Listing | 29.10.2002 |
| Class of Share | Action nominative |
| Nominal Value | 10 CHF |
| Total Shares outstanding (post issue; incl. Greenshore - if any) | 3783081 |
| Allocation Details | |
|---|---|
| Primary Shares | n/a |
| Secondary Shares | n/a |
| Primary Greenshoe | n/a |
| Secondary Greenshoe | n/a |
| Greenshoe Details | |
|---|---|
| Executed | no |
| Ex-date | n/a |
| Executed number of shares | n/a |
| First Trading Day Details | |
|---|---|
| First Trading | 29.10.2002 |
| Price Range | n/a |
| Issue Price | n/a |
| First Open | 47.20 CHF |
| First Close | 48.00 CHF |
| Transaction size in Mio. (incl. executed Greenshoe) | 0 CHF |
| Market Capitalisation in Mio. (based on first closing price) | 182 CHF |
Financial Statement
| Number of Employees | 106 2001 |
| Net Revenues in Mio. | n/a |
| Net Gain in Mio. | n/a |